Kura Oncology (KURA) EPS (Weighted Average and Diluted) (2021 - 2026)
Kura Oncology (KURA) reported EPS (Weighted Average and Diluted) of -$0.83 for Q1 2026, down 25.76% year-over-year from -$1.12 in Q1 2025, and down 136.87% quarter-over-quarter from $2.25 in Q4 2025.
Kura Oncology (KURA) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Kura Oncology (KURA) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.83 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.83, down 25.76% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.34 (down 11.43% YoY), and the FY2025 annual result was -$3.18, down 57.43% from the prior year.
- EPS (Weighted Average and Diluted) declined to -$0.83 in Q1 2026 per KURA's latest filing, from $2.25 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $2.25 in Q4 2025 and troughed at -$0.85 in Q3 2025.
- A 5-year average of -$0.41 and a median of -$0.53 in 2022 frame the typical range for EPS (Weighted Average and Diluted).
- On a YoY basis, EPS (Weighted Average and Diluted) climbed as much as 1123.24% in 2025 and fell as far as 34.23% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.49 in 2022, then retreated by 12.24% to -$0.55 in 2023, then jumped by 60.0% to -$0.22 in 2024, then jumped by 1123.24% to $2.25 in 2025, then tumbled by 136.87% to -$0.83 in 2026.
- Business Quant data shows KURA's EPS (Weighted Average and Diluted) at -$0.83 in Q1 2026, $2.25 in Q4 2025, and -$0.85 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Kura Oncology | 883.44 Mn | 883.44 Mn | 18.00 Mn | -0.83 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.83 |
| Dec 31, 2025 | 2.25 |
| Sep 30, 2025 | -0.85 |
| Jun 30, 2025 | -0.75 |
| Mar 31, 2025 | -0.66 |
| Dec 31, 2024 | -0.22 |
| Sep 30, 2024 | -0.63 |
| Jun 30, 2024 | -0.59 |
| Mar 31, 2024 | -0.59 |
| Dec 31, 2023 | -0.55 |
| Sep 30, 2023 | -0.50 |
| Jun 30, 2023 | -0.53 |
| Mar 31, 2023 | -0.50 |
| Dec 31, 2022 | -0.49 |
| Sep 30, 2022 | -0.53 |
| Jun 30, 2022 | -0.52 |
| Mar 31, 2022 | -0.49 |
| Dec 31, 2021 | -0.50 |
| Sep 30, 2021 | -0.50 |
| Jun 30, 2021 | -0.51 |